: Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease

Gilead Sciences Inc. GILD said Friday the U.S. Food and Drug Administration has approved the use of its Veklury, or remdesivir, for patients with severe renal impairment, including those on dialysis. Veklury is now the only approved COVID antiviral for people with all stages of kidney disease. More than 1 in 7, or 37 million people living in the U.S., are estimated to have chronic kidney disease and are at increased risk of dying of COVID if they get it. The European regulator issued a similar approval in late June. Gilead’s stock has fallen 8% in the year to date, while the S&P 500 SPX has gained 17%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.